ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
University of Turin at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
University of Turin takes part in 11 sessions at ESMO 2026 in Madrid. Its work spans lung cancer, blood cancers, sarcoma, and molecular oncology. Specific studies explore predictors of treatment response in brain tumours and a biomarker for a drug combination in soft-tissue sarcoma.
| Organization | ESMO 2026 Attendance |
|---|---|
University of Turin Turin, Italy | |
Public university in Turin, Italy, with a school of medicine and a molecular biotechnology research centre. | Poster Fri Oct 23 13:00–15:00 Abstract Fri Oct 23 13:30–13:35 Chair Sat Oct 24 08:30–10:00 Proffered Paper: Haematological malignancies Haematological malignancies Abstract Sat Oct 24 09:00–09:10 Invited Discussant 1454O, 1455O and 1456O Haematological malignancies Chair Sat Oct 24 12:00–12:50 ESMO-EACR: What oncologists should know about molecular oncology Biomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Talk Sat Oct 24 12:00–12:15 RAS biology Biomarkers & precision oncology Satellite Sat Oct 24 18:30–18:45 At a pivotal time: Where we stand today Lung & thoracic cancers Talk Sun Oct 25 08:50–09:10 Novel approaches challenging the role of transplantation in the treatment of front-line myeloma Haematological malignancies Satellite Sun Oct 25 13:00–13:05 Welcome and Introductions Lung & thoracic cancers Satellite Sun Oct 25 13:20–14:05 Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate Lung & thoracic cancers Satellite Sun Oct 25 14:25–14:30 Close Lung & thoracic cancers Chair Mon Oct 26 08:30–10:00 Talk Mon Oct 26 08:55–09:20 Abstract Mon Oct 26 09:02–09:07 Poster Mon Oct 26 12:00–12:45 |
Find decision makers at University of Turin
Tell us what you sell and we’ll find the people at University of Turin most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction